Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Indacaterol, a Once‐daily Beta2‐agonist, Versus Twice‐daily Beta2‐agonists or Placebo for Chronic Obstructive Pulmonary Disease." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433523/all/Amodiaquine_for_treating_malaria:_Cochrane_systematic_review. Accessed 19 April 2024.
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433523/all/Amodiaquine_for_treating_malaria:_Cochrane_systematic_review. Accessed April 19, 2024.
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/433523/all/Amodiaquine_for_treating_malaria:_Cochrane_systematic_review
Indacaterol, a Once‐daily Beta2‐agonist, Versus Twice‐daily Beta2‐agonists or Placebo for Chronic Obstructive Pulmonary Disease [Internet]. In: Cochrane Abstracts. [cited 2024 April 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433523/all/Amodiaquine_for_treating_malaria:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
ID - 433523
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433523/all/Amodiaquine_for_treating_malaria:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -